Stock Analysis

Are Poor Financial Prospects Dragging Down Dynamic Medical Technologies Inc. (GTSM:4138 Stock?

TPEX:4138
Source: Shutterstock

It is hard to get excited after looking at Dynamic Medical Technologies' (GTSM:4138) recent performance, when its stock has declined 1.8% over the past month. Given that stock prices are usually driven by a company’s fundamentals over the long term, which in this case look pretty weak, we decided to study the company's key financial indicators. Particularly, we will be paying attention to Dynamic Medical Technologies' ROE today.

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Put another way, it reveals the company's success at turning shareholder investments into profits.

See our latest analysis for Dynamic Medical Technologies

How Is ROE Calculated?

ROE can be calculated by using the formula:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for Dynamic Medical Technologies is:

8.2% = NT$117m ÷ NT$1.4b (Based on the trailing twelve months to September 2020).

The 'return' is the yearly profit. So, this means that for every NT$1 of its shareholder's investments, the company generates a profit of NT$0.08.

What Is The Relationship Between ROE And Earnings Growth?

Thus far, we have learned that ROE measures how efficiently a company is generating its profits. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.

A Side By Side comparison of Dynamic Medical Technologies' Earnings Growth And 8.2% ROE

When you first look at it, Dynamic Medical Technologies' ROE doesn't look that attractive. We then compared the company's ROE to the broader industry and were disappointed to see that the ROE is lower than the industry average of 11%. Therefore, it might not be wrong to say that the five year net income decline of 2.2% seen by Dynamic Medical Technologies was probably the result of it having a lower ROE. However, there could also be other factors causing the earnings to decline. For instance, the company has a very high payout ratio, or is faced with competitive pressures.

So, as a next step, we compared Dynamic Medical Technologies' performance against the industry and were disappointed to discover that while the company has been shrinking its earnings, the industry has been growing its earnings at a rate of 10% in the same period.

past-earnings-growth
GTSM:4138 Past Earnings Growth February 8th 2021

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. It’s important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). This then helps them determine if the stock is placed for a bright or bleak future. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Dynamic Medical Technologies is trading on a high P/E or a low P/E, relative to its industry.

Is Dynamic Medical Technologies Efficiently Re-investing Its Profits?

While the company did payout a portion of its dividend in the past, it currently doesn't pay a dividend. This implies that potentially all of its profits are being reinvested in the business.

Summary

In total, we would have a hard think before deciding on any investment action concerning Dynamic Medical Technologies. The low ROE, combined with the fact that the company is paying out almost if not all, of its profits as dividends, has resulted in the lack or absence of growth in its earnings. So far, we've only made a quick discussion around the company's earnings growth. You can do your own research on Dynamic Medical Technologies and see how it has performed in the past by looking at this FREE detailed graph of past earnings, revenue and cash flows.

If you decide to trade Dynamic Medical Technologies, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted


New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

About TPEX:4138

Dynamic Medical Technologies

Dynamic Medical Technologies Inc., together with its subsidiaries, maintains and markets aesthetic lasers and light-based equipment in Taiwan and Hong Kong.

Excellent balance sheet average dividend payer.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.875% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|24.815% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|4.8887% overvalued
Jonataninho
Jonataninho
Community Contributor